现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2015年
17期
2475-2478
,共4页
张呈%陈昌南%林云笑%苏铭俊%李志建%潘岐作%梁炳钊%陈婵娟%容庭杰%谢峰
張呈%陳昌南%林雲笑%囌銘俊%李誌建%潘岐作%樑炳釗%陳嬋娟%容庭傑%謝峰
장정%진창남%림운소%소명준%리지건%반기작%량병쇠%진선연%용정걸%사봉
肝动脉栓塞化疗%替吉奥%沙利度胺%原发性肝癌
肝動脈栓塞化療%替吉奧%沙利度胺%原髮性肝癌
간동맥전새화료%체길오%사리도알%원발성간암
transcatheter arterial chemoembolization( TACE)%gimeracil and oteracil porassium%thalidomide%hepa-tocellular carcinoma
目的：观察经肝动脉栓塞化疗（ TACE）单用或联合替吉奥与沙利度胺治疗中晚期肝细胞癌（ HCC）的疗效。方法：将2010年8月-2012年8月本院收治的无法手术切除的中晚期HCC患者80例随机分为2组，每组40例。治疗组采用TACE联合替吉奥与沙利度胺口服，对照组仅行TACE治疗。比较两组的有效率、疾病控制率、生存率以及不良反应情况。结果：治疗组有效率67.5％，对照组30.0％，差异有统计学意义（ P＝0.001）；治疗组疾病控制率92.5％，对照组37.5％，差异有统计学意义（ P＝0.000）。治疗组1年生存率80.0％，对照组50.0％，差异有统计学意义（ P＝0.005）；治疗组2年生存率42.5％，对照组10.0％，差异有统计学意义（ P＝0.001）。两组不良反应轻微，主要为恶心呕吐、便秘和骨髓抑制，为I、II级，对症治疗可缓解，两组比较差异无统计学意义（ P>0.05）。结论：替吉奥与沙利度胺联合TACE术对中晚期HCC有一定的治疗价值，值得进一步观察。
目的：觀察經肝動脈栓塞化療（ TACE）單用或聯閤替吉奧與沙利度胺治療中晚期肝細胞癌（ HCC）的療效。方法：將2010年8月-2012年8月本院收治的無法手術切除的中晚期HCC患者80例隨機分為2組，每組40例。治療組採用TACE聯閤替吉奧與沙利度胺口服，對照組僅行TACE治療。比較兩組的有效率、疾病控製率、生存率以及不良反應情況。結果：治療組有效率67.5％，對照組30.0％，差異有統計學意義（ P＝0.001）；治療組疾病控製率92.5％，對照組37.5％，差異有統計學意義（ P＝0.000）。治療組1年生存率80.0％，對照組50.0％，差異有統計學意義（ P＝0.005）；治療組2年生存率42.5％，對照組10.0％，差異有統計學意義（ P＝0.001）。兩組不良反應輕微，主要為噁心嘔吐、便祕和骨髓抑製，為I、II級，對癥治療可緩解，兩組比較差異無統計學意義（ P>0.05）。結論：替吉奧與沙利度胺聯閤TACE術對中晚期HCC有一定的治療價值，值得進一步觀察。
목적：관찰경간동맥전새화료（ TACE）단용혹연합체길오여사리도알치료중만기간세포암（ HCC）적료효。방법：장2010년8월-2012년8월본원수치적무법수술절제적중만기HCC환자80례수궤분위2조，매조40례。치료조채용TACE연합체길오여사리도알구복，대조조부행TACE치료。비교량조적유효솔、질병공제솔、생존솔이급불량반응정황。결과：치료조유효솔67.5％，대조조30.0％，차이유통계학의의（ P＝0.001）；치료조질병공제솔92.5％，대조조37.5％，차이유통계학의의（ P＝0.000）。치료조1년생존솔80.0％，대조조50.0％，차이유통계학의의（ P＝0.005）；치료조2년생존솔42.5％，대조조10.0％，차이유통계학의의（ P＝0.001）。량조불량반응경미，주요위악심구토、편비화골수억제，위I、II급，대증치료가완해，량조비교차이무통계학의의（ P>0.05）。결론：체길오여사리도알연합TACE술대중만기HCC유일정적치료개치，치득진일보관찰。
Objective:To evaluate the clinical effect of transcatheter arterial chemoembolization( TACE)alone or combined with gimeracil and oteracil potassium(S-1)and thalidomide in treatment of advanced hepatocellular carci-noma( HCC). Methods:All 80 patients with unresectable advanced HCC,who were admitted to our hospital from Au-gust 2010 to August 2012,were randomly divided into treatment group(n=40)and control group(n=40). The treat-ment group was treated with TACE combined with S-1 and thalidomide,and the control group with TACE alone. The response rates,disease control rates,survival rates,and adverse reactions of both groups were evaluated. Results:Com-pared with the control group,the treatment group had a significant higher response rate(P =0. 001),a significant higher disease control rate(P=0. 000),a significant higher 1-year survival rate(P=0. 005),and a significant high-er 2-year survival rate(P=0. 001). Mild adverse reactions(grade I or II )were seen in two groups,including nausea,vomiting,constipation,and bone marrow suppression. These adverse reactions could be reduced by symptomatic treat-ment and showed no significant differences between the two groups(P>0. 05). Conclusion:The combination therapy with S-1 and thalidomide plus TACE is effective in the treatment of advanced HCC and is worth further study.
